What is Zacks Research’s Forecast for BHC Q2 Earnings?

Bausch Health Companies Inc. (NYSE:BHC) – Equities researchers at Zacks Research boosted their Q2 2025 EPS estimates for shares of Bausch Health Companies in a note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.05 per share for the quarter, up from their previous estimate of $1.04. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.24 EPS, FY2026 earnings at $4.72 EPS and FY2027 earnings at $5.67 EPS.

Several other equities research analysts also recently commented on the stock. Jefferies Financial Group reiterated a “hold” rating and set a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada cut their target price on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $7.42.

Bausch Health Companies Trading Up 1.3 %

Shares of Bausch Health Companies stock opened at $6.88 on Thursday. The firm has a market capitalization of $2.53 billion, a PE ratio of -57.29, a price-to-earnings-growth ratio of 0.37 and a beta of 0.59. The firm’s 50 day moving average is $7.25 and its 200 day moving average is $7.64. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). The company had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Mountain Hill Investment Partners Corp. acquired a new position in shares of Bausch Health Companies in the 4th quarter worth approximately $56,000. Bank of Nova Scotia acquired a new position in shares of Bausch Health Companies in the 4th quarter worth approximately $83,000. One68 Global Capital LLC acquired a new position in shares of Bausch Health Companies in the 4th quarter worth approximately $90,000. Balyasny Asset Management L.P. acquired a new position in shares of Bausch Health Companies in the 4th quarter worth approximately $97,000. Finally, Alpine Global Management LLC acquired a new position in shares of Bausch Health Companies in the 4th quarter worth approximately $114,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.